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Electroconvulsive therapy for agitation in schizophrenia: meta-
analysis of randomized controlled trials
•Systematic review and meta-analysis•
Background: Agitation poses a significant challenge in the treatment of schizophrenia. Electroconvulsive 
therapy (ECT) is a fast, effective and safe treatment for a variety of psychiatric disorders, but no meta-analysis 
of ECT treatment for agitation in schizophrenia has yet been reported.
Aims: To systematically evaluate the efficacy and safety of ECT alone or ECT-antipsychotics (APs) combination 
for agitation in schizophrenia. 
Methods: Systematic literature search of randomized controlled trials (RCTs) was performed. Two 
independent evaluators selected studies, extracted data about outcomes and safety with available 
data, conducted quality assessment and data synthesis. The Grades of Recommendation, Assessment, 
Development, and Evaluation (GRADE) was used to judge the level of the overall evidence of main outcomes.
Results: Seven RCTs from China, including ECT alone (4 RCTs with 5 treatment arms, n=240) and ECT-APs 
combination (3 RCTs, n=240), were identified. Participants in the studies were on average 34.3(4.5) years of 
age and lasted an average of 4.3(3.1) weeks of treatment duration. All 7 RCTs were non-blinded, and were 
rated as low quality based on Jadad scale. Meta-analysis of the pooled sample found no significant difference 
in the improvement of the agitation sub-score of the Positive and Negative Syndrome Scale (PANSS) when 
ECT alone (weighted mean difference=-0.90, (95% confidence interval (CI): -2.91, 1.11), p=0.38) or ECT-APs 
combination (WMD=-1.34, (95%CI: -4.07, 1.39), p=0.33) compared with APs monotherapy. However, ECT 
alone was superior to APs monotherapy regarding PANSS total score (WMD=-7.13, I2=0%, p=0.004) and its 
excitement sub-score (WMD=-1.97, p<0.0001) as well as the PANSS total score at 14 days (WMD=-7.13, 
I2=0%, p=0.004) and its excitement sub-score at 7 and 14 days (WMD=-1.97 to -1.92, p=0.002 to 0.0001) after 
ECT. The ECT-APs combination was superior to APs monotherapy with respect to the PANSS total score at 
treatment endpoint (WMD=-10.40, p=0.03) and 7 days (WMD=-5.01, p=0.02). Headache ( number-needed-
to-harm (NNH)=3, 95%CI=2-4) was more frequent in the ECT alone group compared to AP monotherapy. 
According to the GRADE approach, the evidence levels of main outcomes were rated as ‘‘very low’’ (37.5%) 
and “low” (50%).
Conclusion: Pooling of the data based on 7 RCTs from China found no advantage of ECT alone or ECT-APs 
combination in the treatment of agitation related outcomes in schizophrenia patients. However, ECT alone or 
ECT-APs combination were associated with significant reduction in the PANSS total score. High-quality RCTs 
are needed to confirm the current interpretations.
Review registration number: CRD42014006689
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1. Introduction
Agitation, excessive motor and/or verbal activity, 
characterized by excitement, restlessness, and psychic 
and motor tension, is common in patients with 
schizophrenia. Agitation can escalate into aggressive 
behavior leading to high risk of injury for patients, 
relatives or staff.[1-3] Furthermore, agitation increases the 
frequency of patient emergency department visits with 
further negative consequences.[4]
In order to minimize the risk posed to self or 
others, agitated patients should be managed, first 
and preferably by non-pharmacological interventions 
such as environmental and behavioral modification, 
and secondly by pharmacological agents.[3-5] However, 
in most cases the management of agitation largely 
depends on pharmacological  agents, [6] mainly 
benzodiazepines and antipsychotics (APs) with their 
well-known adverse effects particularly if they are 
administered repeatedly.[1,3]
Electroconvulsive therapy (ECT) is a fast, effective 
and safe treatment for a variety of psychiatric disorders.
[7] Use of ECT for acute or even prolonged agitation has 
received scant attention in contemporary literature and 
it appears that ECT is hardly ever used for this purpose 
in developed countries. However, ECT remains an option 
for agitation or aggression in China and developing 
countries.[8] There have been a number of studies 
published in China, including randomized controlled 
trials (RCTs)[9-15] to compare the efficacy of ECT alone 
or the ECT-AP combinations to AP monotherapy with 
conflicting results.
To the best of our knowledge, no systematic review 
or meta-analysis of ECT treatment for agitation in 
schizophrenia has been published. This was the impetus 
for this meta-analysis concerning the efficacy and safety 
of ECT treatment for agitation in schizophrenia. 
2. Methods
2.1 Selection of studies
According to PICOS acronym, the inclusion criteria 
were: Participants (P): adult schizophrenia patients 
(≥18 years) with agitation. Intervention (I): ECT 
alone and ECT-AP combination. Comparison (C): AP 
monotherapy. Outcomes (O): primary outcomes were 
the improvement of agitation related outcomes at last-
observation-carried-forward (LOCF) study endpoint 
measured by the Positive and Negative Syndrome Scale 
(PANSS),[16] Brief Psychiatric Rating Scale (BPRS),[17] and 
any other scales or sub-scales or item for agitation: 1) 
total psychopathology scores, 2) the excitement sub-
scores, and 3) the agitation sub-scores. Key secondary 
outcomes included early symptomatic improvement (at 
1, 3, 7, and 14 days), rate of all-cause discontinuation 
and patient-reported adverse events. Study design (S): 
RCT with available data. The exclusion criteria were 
case series, non-randomized studies, and non-original 
research (reviews and meta-analyses).
2.2 Search strategy
English databases (PubMed, PsycINFO, and Cochrane 
Library) and Chinese databases (WanFang Database, 
Chinese Biomedical Database and China Journal 
Net) were searched, from their inception until Feb 
3, 2017 using the following search terms: (1) English 
databases: (ECT OR Electric Convulsive Therap* OR 
Therap*, Electric Convulsive OR Electroshock Therap* 
OR Convulsive Therap*, Electric) OR Electroconvulsive 
Therapy OR Electroconvulsive Therapies OR Therap*, 
Electroconvulsive OR Electric Shock Therap* OR 
Shock Therap*, Electric OR Therap*, Electric Shock OR 
Therap*, Electroshock) AND (schizoaffective disorder 
OR schizophreniform OR Schizophrenic Disorder OR 
Disorder, Schizophrenic OR Schizophrenic Disorders OR 
Schizophrenia OR Dementia Praecox) AND (agitation OR 
exciting OR aggression); (2) Chinese databases: ( 电休克 
OR 电抽搐 OR ECT OR MECT OR 电痉挛 ) AND ( 激越 
OR 攻击 OR 兴奋）AND 随机 AND ( 精神分裂症 OR 
精神分裂 ). The search was supplemented by using the 
“related article” function. Hand-searched reference lists 
from relevant review articles for additional studies were 
hand-searched and authors contacted for unpublished 
data.
2.3 Data extraction
Two independent evaluators (GXJ and ZW) selected 
studies, extracted data, conducted quality assessment 
and data synthesis. Any inconsistencies were resolved 
by discussion to reach consensus or involvement of a 
third reviewer (XYT). 
2.4 Data synthesis and statistical analyses
Clinical outcomes were based on intent-to-treat (ITT) 
analysis, if available. The meta-analysis was performed 
using Review Manager (version 5.3) according to the 
recommendations of the Cochrane Collaboration.[18] To 
combine studies, the random effects model [19] was used 
in all cases. For continuous data and dichotomous data, 
weighted mean differences (WMDs) associated with 
their 95% confidence intervals (CIs) and risk ratio (RR) 
±95% CIs were calculated, respectively. We reported 
the number-needed-to-treat (NNT) or number-needed-
to-harm (NNH) calculated by dividing 1 by the risk 
difference as soon as RR was significant. One study 
[11] from the ‘ECT alone’ group had three study arms. 
According to the methodology of prior meta-analysis,[20] 
we should include each of the 2 ECT arms separately 
in one RCT [11] with 3 treatment arms. Furthermore, 
the APs monotherapy arm was included twice in the 
analysis, but half of all patients were randomized to 
each AP arm in order not to inflate the number of 
patients in the APs monotherapy arm.
In case of I2≥50% for the effect of primary outcome 
on the PANSS total score, a sensitive analysis was 
conducted by excluding one outlying study [15] with 
an outlying effect size (ES) of less than -1.24 (i.e., 
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more than 1.24 standard deviation superiority of ECT-
AP combination) in the ‘ECT-AP combination’ group. 
Furthermore, subgroup and meta-regression analyses 
were conducted to detect the sources of heterogeneity, 
if possible. Publication bias was assessed using funnel 
plots and Egger’s test.[21] All statistical differences were 
considered significant when p<0.05.
2.5 Assessment of study quality 
The Cochrane risk of bias [18] was used to assess the 
quality of each study. Furthermore, the quality of 
each study was also assessed with the Jadad scale 
that assesses study quality on a 5-point scale along 
the following five domains: “randomization,” “double 
blinding,” “description withdrawals and dropouts,” 
“generation of random numbers,” and “allocation 
concealment”.[22] The criteria of high and low quality 
were defined as Jadad score ≥4 and <4, respectively. 
2.6 Clinical evidence recommendation
The grading of recommendations assessment, 
development, and evaluation (GRADE) system [23] 
was used to judge the quality of clinical evidence 
recommendations of the meta-analytic results of ECT 
for agitation in schizophrenia.
3. Results
3.1 Results of the search
Altogether 133 potentially relevant articles from English 
(n=96) and Chinese databases (n=37) were identified; 
duplication excluded 14 studies. Of the remaining 119 
entries, 112 were determined to be irrelevant after 
review of the titles and abstracts, a further 7 were 
removed on the basis of full text review. Finally, 7 RCTs 
with 8 treatment arms met the selection criteria for the 
meta-analysis (Figure 1).
3.2 The characteristics of included studies
The seven RCTs lasted an average of 4.3(3.1) weeks 
(range: 2-8 weeks; median: 2 weeks). The total number 
of participants in all the studies was 480 (range: 30-
100, median: 60). All the RCTs that met our inclusion 
and exclusion criteria were thus included in the meta-
analysis had been conducted in China. Aggregating data 
across all the reviewed trials: there were 240 patients 
in ECT monotherapy vs. AP monotherapy (n=135 vs. 
n=105) comparison and 240 patients in the ECT-AP vs. 
AP monotherapy (n=120 vs. n=120) comparison (Table 
1); patients were on average 34.3(4.5) years old (range: 
31.9-43.5 years; median: 32.5 years) in 6 RCTs with 
available data; 57.6(14.2)% were males (range: 40.0%-
80.0%; median: 56.7%); and the mean illness duration 
with available data (6 RCTs) was 2.7(2.7) years (range: 
0.02-6.1 years; median: 2.2 years). 
3.3 Assessment of risk of bias and quality assessment
The Cochrane risk of bias was presented in Table 2. 
85.7% (6/7) RCTs only mentioned “random” assignment, 
lacking a detailed description of the method of 
randomizing and thus were rated as unclear. However, 
only one RCT [13] using random assignment according to 
the random number table was rated as low risk. Given 
that all included studies were open label, the allocation 
bias, performance bias, and detection bias were rated 
as high risk. None of the included RCTs presented 
the study registration materials, which limited us to 
determine whether or not there was selective reporting 
(i.e., reporting bias). Furthermore, it was impossible 
to judge the other types of biases (e.g., drug company 
sponsorship of the study) due to lack of available 
evidence. Overall, 7 included RCTs suffered from high 
risk of bias and were considered as relatively low-
quality studies. The Jadad score was 2.0(0.6) (range=1-3, 
median=2) (Table 1). All RCTs were rated as low quality 
(Jadad score < 4). Due to pooling of data, less than 3 
RCTs with 4 treatment arms were in all forest plots, 
thus funnel plot analysis to show the presence of risk of 
publication bias could not be conducted.
3.4 The improvement of agitation related outcomes
There were differences between the ECT alone vs AP (4 
RCTs with 5 treatment arms) and ECT-AP vs AP (3 RCTs) 
groups. Moreover, the improvement of agitation related 
outcomes were measured using PANSS in all included 
RCTs.
ECT alone vs AP: ECT alone was superior to AP 
monotherapy with respect to PANSS total score (WMD=-
7.13, (95%CI: -11.99, -2.27), I2=0%, p=0.004, Figure 
2) and excitement sub-score (WMD=-1.97, (95%CI: 
-2.87, -1.08), I2=0%, p<0.0001, Figure 2), but not in 
the agitation sub-score (WMD=-0.90, p=0.38); ECT 
alone was superior to AP monotherapy in PANSS total 
score at 14 days (WMD:-7.13 (95%CI:-11.99, -2.27), 
p=0.004; I2=0%, Supplemental Figure 1), but not at 1 
and 7 days (WMD:-5.23 to -7.13 (95%CI:-16.86, 4.25), 
p=0.06 to 0.24; I2=0% to 77%, Supplemental Figure 1). 
Furthermore, subgroup and meta-regression analyses 
could not be performed due to the limited number of 
RCTs.
Furthermore, ECT alone was superior to AP 
monotherapy in PANSS excitement sub-score at 7 and 
14 days (WMD:-1.97 to -1.92 (95%CI:-3.14, -0.71), 
p=0.002 to 0.0001; I2=0%, Supplemental Figure 2), but 
not at 1 day after ECT treatment (WMD:-1.92 (95%CI:-
4.00, 0.17), p=0.07; I2=35%, Supplemental Figure 2). 
Among the ECT alone studies one RCT [10] used Clinical 
Global Impression (CGI) and found an advantageous 
improvement of psychiatric symptoms in the ECT group 
at 7 and 14 days. 
ECT plus AP vs AP: Regarding the PANSS total 
score, the ECT-AP combination was superior to AP 
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133 articles published before Feb 3, 2017 were identified using a standard search strategy and other sources (see 
methods section):
• 17 from China Journal Net
• 20 from WanFang Database
•   0 from Chinese Biomedical database
• 43 from PubMed
• 50 from PsycINFO
•   3 from Cochrane Library databases
Figure 1.  Identification of included studies
119 unduplicated studies; 24 published in Chinese, 95 in English
105 articles excluded based on title and abstract
14 full-text articles assessed for eligibility
14 duplicates removed
monotherapy (WMD=-10.40, (95%CI: -19.67, -1.12), 
I2=93%, p=0.03, Figure 3), but not in the excitement and 
agitation sub-scores (WMD=-1.06 to -1.34, p=0.33 to 
0.37). The significant difference between the two groups 
in the PANSS total score disappeared after one outlying 
study [15] was removed (WMD:-4.23 (95%CI:-8.89, 0.43), 
p=0.08; I2=76%). Furthermore, subgroup and meta-
regression analyses could not be performed due to the 
limited number of RCTs.
Furthermore, adding ECT to AP was superior to 
AP monotherapy at 7 days for the PANSS total score 
(WMD=-5.01, (95%CI: -9.37, -0.66), I2=14%, p=0.02, 
Figure 4), but not to PANSS total score (p=0.15), 
excitement (p=0.35) and agitation sub-scores (p=0.44) 
at 14 days (Figures 4). 
3.5 Side effects and discontinuation rate
The Treatment Emergent Symptom Scale (TESS) was 
generally used to assess adverse drug reactions (ADRs) 
in these RCTs however such data were not available in 
1 RCT (Table 1). None of the included RCTs reported the 
rate or cause of treatment discontinuation.
ECT alone vs APs: Headache (p=0.0001, NNH=3, 
95%CI=2-4) was the only ADRs more frequent in 
the ECT alone group compared to AP monotherapy 
(Supplemental Figure 3). There was significantly 
less akathisia (p=0.02, NNH=8, 95%CI=5-17) and 
electrocardiogram changes (p=0.05) with borderline 
significance in the ECT alone group compared to the AP 
group. Meta-analysis of uroclepsia, weight gain, upper 
7 full-text articles excluded:
• 1 duplicate publication 
• 1 lack of specific diagnosis
• 2 using intramuscular injection clonazepam
• 1 risperidone combined with ECT versus Haloperidol 
• 2 antipsychotic combined with ECT versus two different  
               antipsychotics combination
7 studies included in qualitative synthesis
7 studies with 8 treatment arms included in qualitative synthesis
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Table 2. Evaluation of risk of bias in the seven included studies
study sequence generation
allocation 
sequence 
concealment
blinding of 
participants and 
personnel
blinding of 
outcome 
assessment
incomplete 
outcome 
data
selective 
outcome 
reporting
other potential 
threats to 
validity
Pan 
2015 [15] unclear high high high low unclear unclear
Peng et al 
2014 [13] low high high high low high unclear
Yang et al 
2005 [9] unclear high high high low unclear unclear
Guo et al 
2009[10] unclear high high high low unclear unclear
Li 
2015 [14] unclear high high high low unclear unclear
Yuan et al 
2012 [12] unclear high high high unclear unclear unclear
Shen et al 
2011 [11] unclear high high high unclear unclear unclear
Figure 2. ECT alone for agitation in schizophrenia: forest plot for the Positive and Negative Syndrome Scale 
(PANSS) total score and its PANSS excitement and agitation sub-scores at endpoint
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respiratory infections, tremor, dry mouth, insomnia, and 
electroencephalography changes did not differ between 
the groups (Supplemental Figure 3).
ECT plus AP vs AP: Only two RCTs [9,13] reported the 
ADRs without meta-analyzable data.
3.6 Clinical evidence recommendation
Clinical evidence recommendation of the main meta-
analytic outcomes based on the GRADE approach 
showed some limitations of risk of bias, inconsistency 
and publishing bias, and no obvious indirectness or 
imprecision. According to the above assessments, the 
quality of evidence of 8 outcomes presented in Table 3 
and ranged from ‘‘very low’’ (37.5%), “low” (50%), to 
‘‘high’’ (12.5%).
4. Discussion
4.1 Main findings
Despite a systematic literature search in both English 
and Chinese-language databases, we only identified 7 
RCTs with 8 treatment arms that examined the efficacy 
and safety of using ECT for the treatment of agitation 
in 480 patients with schizophrenia who are currently 
using APs. All included RCTs were open label and the 
assessment of outcomes was not blinded in all trials. 
Furthermore, the quality of all included RCTs was rated 
as ‘low quality’ based on Jadad scale. Overall, the 
results suggest that both ECT alone and the ECT-AP 
combination over 2 to 8 weeks had superior efficacy to 
AP monotherapy regarding the reduction in PANSS total 
score, but not in the agitation sub-score. ECT and ECT-
AP combination were both safe and well tolerated. The 
reduction in the total PANSS score with ECT alone was 
superior to AP monotherapy as early as at 1 day with 
a moderate effect size of -0.52, which increased to a 
relatively larger effect size of -0.60 after 14 days. The 
ECT-AP combinations were significantly superior to AP 
monotherapy with respect to PANSS total score at 7 days 
with a small effect size of -0.36. However, 35 patients 
reported headache (38.9% vs. 0% on APs monotherapy, 
NNH=3), which was significantly more common in the 
ECT alone group. These adverse effects were transient 
and mild.[10,11]
Figure 3. Add-on ECT to antipsychotics for agitation in schizophrenia: forest plot for the Positive and Negative 
Syndrome Scale (PANSS) total score and its excitement and agitation sub-scores at endpoint
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4.2 Limitations
Several limitations need to be acknowledged. First, 7 
RCTs (100%) reviewed were rated as low quality and 
the strength of the evidence for 87.5% outcomes was 
rated as “very low” or “low” according to the GRADE 
approach. However, strong recommendations does not 
necessarily imply high quality evidence and low quality 
evidence can still result in strong recommendations.[23] 
Further, the RCTs were inconsistent in their methodology 
with respect to sampling and the delivery of ECT and the 
type and dose of antipsychotic medications. Subgroup 
analyses and meta-regression cannot be employed to 
lessen the heterogeneity of primary outcomes. Second, 
data regarding the cognitive effects of ECT were not 
systematically assessed in the included studies. In 
addition, agitation, the target symptom in this study, 
was evaluated with a single item in the PANSS, rather 
than with a standardized rating scale. Furthermore, 
some more variables potentially associated with 
agitation, such as the quality of care and patients’ 
education, were not assessed in included studies. Third, 
treatment adherence was not routinely assessed or 
reported. In particular, the ECT dose-response effects 
on agitation when used as monotherapy or/and co-
treatment in agitation patients with schizophrenia, 
definitely needs to be more fully evaluated. Finally, all 
studies were conducted in China thus the findings need 
to be replicated in other countries.
4.3 Implications
Although this paper included 7 low quality RCTs with 
small samples and the methodological limitations [23] 
identified, the thorough methodology of this meta-
analysis included the assessment of quality using 
the Cochrane risk of bias, [18] Jadad scale [22], and 
GRADE system.[23] The heterogeneity of PANSS total 
score assessed by I2 decreased from 93% to 76% 
after removing one outlying study;[15] in addition, 
the significance disappeared, which could be due 
Figure 4. Add-on ECT to antipsychotics for agitation in schizophrenia: forest plot for the Positive and Negative 
Syndrome Scale (PANSS) total score at 7 and 14 days as well as PANSS agitation and excitement sub-
score at 14 days
4.1 PANSS Total Score (7 days)
Pan 2015
Peng 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 2.62; Chi² = 1.16, df = 1 (P = 0.28); I² = 14%
Test for overall effect: Z = 2.26 (P = 0.02)
4.2 PANSS Total Score (14 days)
Pan 2015
Peng 2014
Yang 2005
Subtotal (95% CI)
Heterogeneity: Tau² = 134.46; Chi² = 41.62, df = 2 (P < 0.00001); I² = 95%
Test for overall effect: Z = 1.43 (P = 0.15)
4.3 PANSS Excitement Sub-Score (14 days)
Peng 2014
Yang 2005
Subtotal (95% CI)
Heterogeneity: Tau² = 8.36; Chi² = 19.35, df = 1 (P < 0.0001); I² = 95%
Test for overall effect: Z = 0.93 (P = 0.35)
4.4 PANSS Agitation Sub-sore (14 days)
Peng 2014
Yang 2005
Subtotal (95% CI)
Heterogeneity: Tau² = 0.85; Chi² = 3.44, df = 1 (P = 0.06); I² = 71%
Test for overall effect: Z = 0.77 (P = 0.44)
Mean
78.4
27.25
68.2
23.84
59.38
1.07
9.67
1.01
8.24
SD
26.9
8.12
22.6
7.55
8.66
0.23
3.73
0.18
2.61
Total
50
40
90
50
40
30
120
40
30
70
40
30
70
Mean
78.2
33.21
75.3
25.62
80.06
1.02
13.82
1.03
9.81
SD
27.4
7.92
25.1
8.15
9.51
0.44
3.64
0.49
3.73
Total
50
40
90
50
40
30
120
40
30
70
40
30
70
Weight
15.4%
84.6%
100.0%
30.6%
35.0%
34.4%
100.0%
52.5%
47.5%
100.0%
64.2%
35.8%
100.0%
IV, Random, 95% CI
0.20 [-10.44, 10.84]
-5.96 [-9.48, -2.44]
-5.01 [-9.37, -0.66]
-7.10 [-16.46, 2.26]
-1.78 [-5.22, 1.66]
-20.68 [-25.28, -16.08]
-9.91 [-23.51, 3.69]
0.05 [-0.10, 0.20]
-4.15 [-6.01, -2.29]
-1.94 [-6.05, 2.17]
-0.02 [-0.18, 0.14]
-1.57 [-3.20, 0.06]
-0.57 [-2.03, 0.88]
ECT Control Mean Difference Mean Difference
IV, Random, 95% CI
-20 -10 0 10 20
ECT is better Control is better
Secondary outcomes
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to the decreased sample size thereby reducing the 
power detecting significant results. The previous 
meta-analyses[24-25] supported our interpretation that 
adjunctive ECT can be an efficacious treatment for 
improving total psychopathology in schizophrenia 
patients. Agitation poses a significant challenge in the 
treatment of schizophrenia.[1] However, the current 
meta-analysis of 7 relatively low quality RCTs showed 
that both ECT alone and the ECT-AP combination are 
ineffective treatments for agitation in 480 Chinese 
schizophrenia patients. This meta-analysis indicates 
that other symptoms (e.g. hallucination, delusion, etc.) 
maybe respond better to ECT when compared with 
agitation related outcomes in schizophrenia patients. 
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Table 3. GRADE Analyses for main primary and secondary outcomes: ECT for agitation in schizophrenia
Outcomes N (arms) Risk of bias Inconsistency Indirectness Imprecision
Publication 
bias
Large 
effect
Overall quality 
of evidencea
ECT alone vs. APs
PANSS total score 90 (2) Seriousb No No No Seriousd No Low
PANSS excitement 
sub-score 180 (4) Serious
b No No No Seriousd No Low
PANSS agitation 
sub-score 30 (1) Serious
b No No No Seriousd No Low
Headache 180 (3) Seriousb No No No Seriousd Very largee High
Akathisia 180 (3) Seriousb No No No Seriousd No Low
ECT+ APs vs. APs
PANSS total score 240 (3) Seriousb Seriousc No No Seriousd No Very Low
PANSS excitement 
sub-score 140 (2) Serious
b Seriousc No No Seriousd No Very Low
PANSS agitation 
sub-score 140 (2) Serious
b Seriousc No No Seriousd No Very Low
APs = antipsychotics; ECT = Electroconvulsive therapy; GRADE = grading of recommendations assessment, development, and evaluation; 
PANSS = Positive and Negative Syndrome Scale
aGRADE Working Group grades of evidence: High quality=further research is very unlikely to change our confidence in the estimate of 
effect. Moderate quality=further research is likely to have an important impact on our confidence in the estimate of effect and may 
change the estimate. Low quality=further research is very likely to have an important impact on our confidence in the estimate of effect 
and is likely to change the estimate. Very low quality=we are very uncertain about the estimate.
bAll studies reported as having a serious bias used a open label method, only mentioned random allocation without describing the 
method and withdrawal from the study.
cAll studies reported as having a serious inconsistency had I2> 50%.
dFor continuous outcomes, N < 400; For dichotomous outcomes, N<300.
eThe results of meta-analytic outcomes: RR>5 or <0.2
• 10 • Shanghai Archives of Psychiatry, 2017, Vol. 29, No. 1
背景：躁动在精神分裂症治疗中是一个重大挑战。电
休克疗法（ECT）对各种精神疾病是一种快速、有效、
和安全的治疗，但 ECT 对精神分裂症的躁动治疗的相
关 meta 分析还尚未报道。
目标：系统地评估单一使用 ECT 或 ECT 合并使用其他
抗精神病药物（APs）的对精神分裂症的躁动治疗的有
效性和安全性。
方法：进行随机对照试验（RCT）的系统文献搜索。
两名独立评估者筛选研究、提取结果数据与现有数据
的安全性、进行质量评估和数据合成。采用建议、评估、
开发、和评价的工作组等级（GRADE）来判断主要成
果的证据的总体水平。
结果：一共确定了中国有七个 RCTs，包括 ECT 单一
使用（4 个 RCTs 有 5 个治疗组，n = 240）和 ECT-APs
合并使用（3 个 RCTs，n = 240）。研究对象平均年龄
34.3（4.5）岁，平均治疗时间为 4.3（3.1）周。所有 7
个 RCTs 非盲法，并且根据 Jadad 量表 7 项 RCTs 均被评
为低质量。样本的Meta分析发现与 APs单一治疗相比，
单一使用 ECT 或 ECT-APs 合并使用阳性和阴性症状量
表（PANSS）的躁动子因子评分改善均无显著性差异（ECT
单一使用 : weighted mean difference（WMD）=-0.90, 
95% confidence interval (CI): (-2.91, 1.11), p=0.38; ECT-APs
合并使用：WMD=-1.34, (95%CI: -4.07, 1.39), p=0.33）。
然而，PANSS 总分（WMD=-7.13, I2=0%, p=0.004）和
兴奋子因子评分（WMD=-1.97,  p<0.0001）、ECT 治疗
14 天后的 PANSS 总分（WMD=-7.13, I2=0%, p=0.004）
和第 7 天和第 14 天的兴奋子因子评分（WMD=-1.97 
to -1.92, p=0.002 to 0.0001）均显示单一使用 ECT 优
于 APs 单一治疗。ECT-APs 合并治疗结束时（WMD=-
10.40, p=0.03）和治疗后 7 天（WMD=-5.01, p=0.02）的
PANSS 总分显示均优于 APs 单药治疗。头痛（p=0.0001, 
number-needed-to-harm (NNH)=3, 95%CI=2-4）是唯一
的 ECT单一治疗后不良反应，并且 ECT 单一治疗组比
APs 单药治疗发生的更频繁。根据 GRADE 方法，主要
结果的证据水平被评为 “ 非常低 ”（37.5%）和 “ 低 ”
（50%）。
结论：基于中国 7 个 RCTs 合并的数据发现 ECT 单一治
疗或 ECT-APs 合并治疗在精神分裂症患者的躁动治疗
中并没有优势。然而，ECT 单一治疗或 ECT-APs 合并治
疗均与 PANSS 总分减低显著有关。需要高质量的 RCTs
验证目前的解释。
关键词：电休克治疗；躁动；精神分裂症；头痛，
meta 分析
电休克治疗用于精神分裂症的激越症状：随机对照试验的meta 分析
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Supplemental Figure 1. ECT alone for agitation in schizophrenia: forest plot for the Positive and Negative 
Syndrome Scale (PANSS) total score at 1, 7, and 14 days
Secondary outcomes
Notice for soliciting papers for the 14th academic conference of the Chinese Society of 
Neuroscience & Psychiatry (CSNP)
“The 14th annual academic conference of the Chinese Society of Neuroscience & Psychiatry”, which is hosted by 
CSNP, and undertaken by Mental Health Center of Shanghai Jiao Tong University’s medical school and Shandong 
Mental Health Center, will be held in the Luneng Hilton Hotel in Jinan, Shandong, from 29th June to 1st July, 2017.  
    The present society welcomes paper submissions and conference participations. The conference affair group 
accepts abstracts (objectives, methods, results and conclusions) under 1000 words. The website used for paper 
submissions and registrations is http://61.147.124.137:8088/2017/default.aspx. The academic committee of this 
conference will review papers and select high quality reports for presentation at the conference. We look forward to 
your participation and support! The deadline for paper submission is 1st June, 2017.
    We welcome colleagues from all over China and abroad to participate in this conference held in scenic Jinan. We 
are looking forward to a lively discussion on developments in the field. 
Dates: 29th June to 1st July, 2017 (check in on 29th June)
Address: Luneng Hilton Hotel in Jinan, Shandong, No.2888 South Erhuan Lu, Central District in Jinan
Cost arrangement: The registration fee, travel fee and accommodation fee are at your own expense. The 
registration fee is 1000 yuan (Shandong representatives and graduate students with student IDs can pay half of 
the registration fee). The accommodation fee from 30th June to 1st July 2017 is 500 yuan per standard room. 
Contact: Ruizhi Mao 18221768225
E-mail：csnpmeeting@163.com                         
Chinese Society of Neuroscience & Psychiatry
                                                              4th February 2017 
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Supplemental Figure 2. ECT alone for agitation in schizophrenia: forest plot for the Positive and Negative 
Syndrome Scale (PANSS) excitement sub-score at 1, 7, and 14 days
Secondary 
Erratum
Li HB, Wang Y, Jiang J, Li W, Li CB. Effects of transcranial direct current stimulation (tDCS) for auditory hallucinations: 
A systematic review. Shanghai Arch Psychiatry. 2016; 28(6):301-308. doi: http://dx.doi.org/10.11919/
j.issn.1002-0829.216121
In the Figure 1 (identification of included studies) of the paper, the number in the first box “304 potential 
articles published before 13 February 2016 were identified…” should be “432 potential articles published 
before 13 February 2016 were identified…”. This change was been made to the online version on the 
Shanghai Archives of Psychiatry website as of 10 Jan, 2017.
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Supplemental Figure 3. ECT alone for agitation in schizophrenia: forest plot for adverse events 
Secondary outcomes
3.1 Headache
Guo 2009
Shen 2011a
Shen 2011b
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 2 (P = 0.96); I² = 0%
Test for overall effect: Z = 3.86 (P = 0.0001)
3.2 Akathisia
Guo 2009
Shen 2011a
Shen 2011b
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.49, df = 2 (P = 0.78); I² = 0%
Test for overall effect: Z = 2.38 (P = 0.02)
3.3 Electrocardiogram changes
Li 2015
Yuan 2012
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.27, df = 1 (P = 0.60); I² = 0%
Test for overall effect: Z = 1.94 (P = 0.05)
3.4 Uroclepsia
Shen 2011a
Shen 2011b
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.48, df = 1 (P = 0.49); I² = 0%
Test for overall effect: Z = 1.78 (P = 0.08)
3.5 Weight Gain
Shen 2011a
Shen 2011b
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
3.6 Upper Respiratory Infection
Shen 2011a
Shen 2011b
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
3.7 Tremor
Guo 2009
Shen 2011a
Shen 2011b
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 11.23; Chi² = 13.03, df = 2 (P = 0.001); I² = 85%
Test for overall effect: Z = 0.39 (P = 0.70)
3.8 Dry mouth
Shen 2011a
Shen 2011b
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
3.9 Insomnia
Shen 2011a
Shen 2011b
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
3.10 Electroencephalogram changes
Li 2015
Yuan 2012
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.31; Chi² = 6.35, df = 1 (P = 0.01); I² = 84%
Test for overall effect: Z = 0.75 (P = 0.45)
Events
8
14
13
35
0
0
0
0
11
4
15
6
1
7
0
0
0
0
0
0
0
10
7
17
0
0
0
0
0
0
12
11
23
Total
30
30
30
90
30
30
30
90
30
15
45
30
30
60
30
30
60
30
30
60
30
30
30
90
30
30
60
30
30
60
30
15
45
Events
0
0
0
0
8
2
2
12
19
5
24
0
0
0
1
1
2
1
1
2
13
0
0
13
1
1
2
1
1
2
25
10
35
Total
30
30
30
90
30
30
30
90
30
15
45
30
30
60
30
30
60
30
30
60
30
30
30
90
30
30
60
30
30
60
30
15
45
Weight
32.8%
33.6%
33.5%
100.0%
36.3%
31.9%
31.9%
100.0%
80.5%
19.5%
100.0%
55.5%
44.5%
100.0%
50.0%
50.0%
100.0%
50.0%
50.0%
100.0%
33.4%
33.3%
33.3%
100.0%
50.0%
50.0%
100.0%
50.0%
50.0%
100.0%
50.1%
49.9%
100.0%
M-H, Random, 95% CI
17.00 [1.03, 281.91]
29.00 [1.81, 465.07]
27.00 [1.68, 434.53]
23.76 [4.75, 118.76]
0.06 [0.00, 0.98]
0.20 [0.01, 4.00]
0.20 [0.01, 4.00]
0.13 [0.02, 0.70]
0.58 [0.34, 1.00]
0.80 [0.27, 2.41]
0.62 [0.38, 1.00]
13.00 [0.76, 220.96]
3.00 [0.13, 70.83]
6.77 [0.82, 55.80]
0.33 [0.01, 7.87]
0.33 [0.01, 7.87]
0.33 [0.04, 3.12]
0.33 [0.01, 7.87]
0.33 [0.01, 7.87]
0.33 [0.04, 3.12]
0.04 [0.00, 0.60]
21.00 [1.29, 342.93]
15.00 [0.89, 251.42]
2.26 [0.04, 139.34]
0.33 [0.01, 7.87]
0.33 [0.01, 7.87]
0.33 [0.04, 3.12]
0.33 [0.01, 7.87]
0.33 [0.01, 7.87]
0.33 [0.04, 3.12]
0.48 [0.30, 0.77]
1.10 [0.69, 1.76]
0.73 [0.32, 1.67]
ECT Control Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.001 0.1 1 10 1000
ECT is better Control is better
